Celltrion, Inc. Logo

Celltrion, Inc.

A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.

068270 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
인천광역시 연수구 아카데미로 23, 인천광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Celltrion, Inc. is a leading global biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of innovative therapeutics. A pioneer in the biosimilar field, Celltrion launched the world's first monoclonal antibody biosimilar and continues to be a market leader. The company's portfolio includes a range of biosimilars and novel drugs targeting therapeutic areas such as immunology, oncology, hematology, and endocrinology. Celltrion provides comprehensive, end-to-end solutions across the biopharmaceutical value chain, from R&D and clinical trials to production and sales, with a commitment to improving worldwide patient access to high-quality, affordable medicines.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Celltrion, Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 724.1 KB
2025-09-17 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득결정)
Korean 33.3 KB
2025-09-08 00:00
Related Party Transaction
임원ㆍ주요주주특정증권등거래계획보고서
Korean 70.7 KB
2025-09-05 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.0 KB
2025-09-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.5 KB
2025-09-01 00:00
Legal Proceedings Report
투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 유럽 임상 3상 시험계획 승인(Part2))
Korean 12.2 KB
2025-09-01 00:00
Major Shareholding Notification
대규모기업집단현황공시[분기별공시(개별회사용)]
Korean 31.0 KB
2025-08-27 00:00
Regulatory News Service
풍문또는보도에대한해명(미확정)
Korean 7.9 KB
2025-08-25 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.5 KB
2025-08-19 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 747.4 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 5.6 MB
2025-08-14 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.5 KB
2025-08-13 00:00
Regulatory News Service
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Korean 11.0 KB
2025-08-13 00:00
Transaction in Own Shares
자기주식취득결과보고서
Korean 28.3 KB
2025-08-07 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.8 KB

Automate Your Workflow. Get a real-time feed of all Celltrion, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Celltrion, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Zealand Pharma Logo
Developing innovative peptide medicines for metabolic and inflammatory diseases.
Denmark ZEAL
Zelluna ASA Logo
Developing off-the-shelf TCR-NK cell therapies to treat patients with solid cancers.
Norway ULTI
Zentiva 2 Logo
European provider of high-quality, affordable generic and over-the-counter medicines.
Slovakia SKF
Zentiva S.A. Logo
Develops and distributes affordable generic, OTC, and specialty medicines across Europe.
Romania SCD
ZERIA PHARMCEUTICAL CO., LTD. Logo
Develops and distributes prescription & consumer healthcare products in Europe and Asia.
Japan 4559
株式会社PRISM BioLab Logo
A biotech creating novel drugs by targeting previously "undruggable" protein interactions.
Japan 206A

Talk to a Data Expert

Have a question? We'll get back to you promptly.